Biotech Analysts Fadia & Lee, along with Dr. Mark Scarupa, Asthma Allergy/Allergy Specialist at the Institute For Asthma & Allergy, discuss Blueprint Medicines’ Ayvakit for Indolent Systemic Mastocytosis (ISM), the updated PIONEER data presented at AAAAI and the potential competitive impact from Cogent Biosciences’ Bezuclastinib on an Analyst/Industry conference call to be held on February 27 at 11:30 am.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BPMC:
- Blueprint Medicines to hold a conference call
- Needham biotech analysts to hold an analyst/industry conference call
- Blueprint Medicines presents registrational data from PIONEER trial AYVAKIT
- Blueprint Medicines price target lowered to $38 from $45 at SVB Securities
- Blueprint Medicines to regain global rights to gavreto from Roche